Dec. 10, 2002 — Graffinity Pharmaceuticals AG, German microarray drug discovery platform developer, said it has named Klaus Schollmeier chief executive officer starting Jan. 1.

Schollmeier most recently served as managing director of the Healthcare/Biotechnology Group at ING-BHF Bank for ING Group Europe, and held various senior management posts within BASF’s pharmaceutical division. He replaces Dirk Vetter, Graffinity co-founder and former CEO, who leaves launch Complex Biosystems, a new German drug-delivery venture.

Graffinity said it seeks to commercialize its chemical genomics technology, which combines chemistry, physics, information technology and microsystems to screen potential drug targets. The firm, which has signed deals with Pfizer, Aventis Pharma and Eli Lilly, was formed in 1997 and has about 90 employees.